It always seems impossible until it is done. Nelson Mandela
Idea Transcript
Home
Enter Ticker, Guru, Company, etc.
FilingWiz
Gurus
Insiders
Market
Articles
Conference
Forum
Go
Subscribe
Log In
Tutorials
My Portfolios
Get 7-Day Free Trial
My Gurus
GF Chat
Search
Screeners
100
PRNewswire
1. How to use GuruFocus - Tutorials
Articles
2. What Is in the GuruFocus Premium Membership?
Bookmark
Print
Tweet
Share
3. A DIY Guide on How to Invest Using Guru Strategies
IMBRUVICA® (ibrutinib) Data Provide Insights Into Its Potential Treatment Benefits for Previously-Treated Chronic Graft-Versus-Host Disease -- A Serious, Possibly Life-Threatening Condition December 11, 2017
Join the forum
| About: NYSE:ABBV +0%
to win a value investing book - Clinical results suggest that ibrutinib inhibits B cells and follicular helper T cells believed to play a critical role in treating chronic graft-versus-host disease (cGVHD), while preserving immune memory and Th1 T cells - Data build on the scientific understanding of IMBRUVICA in previouslytreated adults with cGVHD - IMBRUVICA is the first therapy specifically approved for adults with cGVHD after failure of one or more lines of systemic therapy - This press release corresponds to abstract #4481
(/flarum) Salesforce.com Inc - Do you see any value? (/flarum/d/167221) 8 EPV (/flarum/d/177137) 1 Excel Add-in Program (/flarum/d/175915) 1 Valeant (/flarum/d/168934) 18 PHARMA - AGN (Allergan), CELG good buy? (/flarum/d/175811) 4 How is TTM calculated? (/flarum/d/174469) 2 The History of Sears Predicts Nearly Everything Amazon Is Doing (/flarum/d/149761) 4
PR Newswire
Allergan - WTF? (/flarum/d/174023) 9
NORTH CHICAGO, Ill., Dec. 11, 2017
When the Market Slumps, are Structured Annuities the Way to Go? (/flarum/d/175517) 1 Why AAPL keep increasing its debt? (/flarum/d/164584) 7 My Take On CenturyLink, Its Free Cash Flow And Dividend (/flarum/d/174974) 1
Access the Forum! (/flarum) NORTH CHICAGO, Ill., Dec. 11, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced new data on the biologic and cellular mechanisms of IMBRUVICA® (ibrutinib) in patients with chronic graft-versus-host disease (cGVHD), a potentially life-threatening consequence of an allogeneic stem cell or bone marrow transplant.1 New results
Performances of the stocks mentioned by PRNewswire
Õ
User Generated Screeners
Õ
showed ibrutinib selectively inhibited pre-germinal center B cells and follicular helper T cells (Tfh) that are believed to play a critical role in treating cGVHD. In addition, the data also showed that ibrutinib preserved immune memory and Th1 T cells, which suggests the potential for additional treatment benefit. These results were observed in a Phase 1b/2 trial (PCYC-1129).